To view the video full screen, click on the small button next to the volume control in the lower right hand corner.
Dana-Farber Cancer Institute
Boston, MA, USA
Future translational research in multiple myeloma (MM) will focus on the development of molecularly-based combination therapies to achieve high frequency and durable responses in the majority of patients. Combination therapies have proven to be curative in childhood acute lymphoblastic leukemia, Hodgkins disease, and testicular cancer among others. Already cytogenetic abnormalities known to carry adverse prognostic import to conventional and high dose therapies do not apply to novel therapies (bortezomib, lenalidomide), which will serve as platform drugs for future combined therapies.